Genetic tests may pinpoint who should get Avastin October 4th, 2008 By Ben Hirschler LONDON, Oct 3 (Reuters) - Genetic tests could in future showwho will respond best to Genentech (DNA.N: Quote, Profile, Research, Stock Buzz) and Roche’s (ROG.VX: Quote, Profile, Research, Stock Buzz)blockbuster cancer drug Avastin — a positive development forpatients but not necessarily for sales. Scientists writing in the latest issue of the Journal ofClinical Oncology said they had identified two geneti
Originally posted here:
Genetic tests may pinpoint who should get Avastin
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.